Myriad Genetics Demonstrates Strong Commitment to Preventing Hereditary Colon Cancer as Part of National Colorectal Cancer Aw...
March 01 2018 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, continues to demonstrate an
unmatched commitment to hereditary cancer risk assessment and
genetic testing during National Colorectal Cancer Awareness
Month.
As the third most commonly diagnosed cancer in both men and
women in the United States, colon cancer kills one person every 10
minutes. More than 140,000 new cases of colon cancer are
expected to be diagnosed this year alone. According to the
American Cancer Society, one in 22 men and one in 24 women will be
diagnosed with colorectal cancer in their lifetime. It is
estimated that five to 10 percent of all colon cancers are caused
by an inherited genetic mutation that is passed on from parent to
child.
“Myriad has been a pioneer in the field of hereditary cancer
risk assessment for colon cancer for more than 20 years, and that
commitment continues today,” said Johnathan Lancaster, M.D., Ph.D.,
chief medical officer, Myriad Genetics, Inc. “We believe that
knowledge is power, and for many patients with colon cancer,
genetic testing can make a real difference to them and to the lives
of their family members.”
The leading genetic test for hereditary colon cancer risk
assessment is called myRisk® Hereditary Cancer. People can
take the Hereditary Cancer Quiz to determine if they might be
suitable candidates for genetic testing. The quiz results
provide helpful information that people can use to discuss their
personal risk of colon cancer with their healthcare
professional.
“If you have a family history of colon, ovarian, and/or
uterine/endometrial cancer, it could be caused by a hereditary
cancer syndrome,” said Sapna Syngal, M.D., director of research at
the Center for Cancer Genetics and Prevention at Dana-Farber
Cancer Institute in Boston. “And if you have colon
cancer and were diagnosed before 50 years of age, you should
definitely pursue discussions about genetic testing.”
Myriad Joins Forces with #StrongArmSelfie Social
Media CampaignMyriad is committed to advocating for
patients with colon cancer and is collaborating with Fight
Colorectal Cancer throughout March. As such, Myriad will
sponsor the #StrongArmSelfie social media
campaign, donating $1 to Fight Colorectal Cancer for the
first 5,000 people who share selfies using #StrongArmSelfie.
A #StrongArmSelfie is an easy way to show support in the fight
against colorectal cancer. All people need to do is post or
share a photo onto a public Twitter or Instagram account with the
hashtag #StrongArmSelfie. For more information about how to
participate in the #StrongArmSelfie campaign, visit
www.fightcolorectalcancer.org.
“We are very excited that Myriad Genetics is showing its support
in the fight against colorectal cancer and the #StrongArmSelfie
campaign,” said Michell Baker, director of Partnership Development
at Fight Colorectal Cancer. “We’ve already seen
#StrongArmSelfie posts from people all over the world! Famous
individuals like Coach Jim Harbaugh, Bear Grylls, Luke
Perry, the hosts of The Doctors TV show and more have flexed for a
#StrongArmSelfie to show their support for the cause.”
About myRisk® Hereditary Cancer and
Patient AccessmyRisk Hereditary Cancer is a 28-gene panel
and helps doctors understand an unaffected person’s risk of
developing hereditary colon cancer using genetic testing and family
history. In contrast, for those already diagnosed with colon
cancer, the myRisk test can help identify their risk of secondary
cancers, help inform medical management, and may help prevent
cancer in unaffected family members who inherited a cancer-causing
mutation.
Patients can access myRisk a number of ways, including through
health insurance coverage from an employer-sponsored health plan, a
health insurance exchange plan or a program like Medicare or
Medicaid. Myriad also offers financial assistance programs
for those who may have trouble accessing tests or lack
coverage. The Company has provided more than $76 million in
financial assistance to patients over the past five fiscal
years. Learn more at https://myriadpromise.com/
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: maintaining leadership in an
expanding hereditary cancer market, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary
Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, Vectra DA, GeneSight, EndoPredict and Prolaris are
trademarks or registered trademarks of Myriad Genetics, Inc. or its
wholly owned subsidiaries in the United States and foreign
countries. MYGN-F, MYGN-G
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to related to Myriad’s continued and
demonstrated commitment to hereditary cancer risk assessment and
genetic testing during Colon Cancer Awareness Month; Myriad’s
collaboration with Fight Colorectal Cancer; Myriad’s sponsorship of
the #StrongArmSelfie social media campaign; and the Company’s
strategic directives under the caption “About Myriad Genetics.”
These “forward-looking statements” are based on management’s
current expectations of future events and are subject to a number
of risks and uncertainties that could cause actual results to
differ materially and adversely from those described or implied in
the forward-looking statements. These risks include, but are not
limited to: the risk that sales and profit margins of our existing
molecular diagnostic tests and pharmaceutical and clinical services
may decline or will not continue to increase at historical rates;
risks related to our ability to transition from our existing
product portfolio to our new tests; risks related to changes in the
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over genetic testing in general or
our tests in particular; risks related to regulatory requirements
or enforcement in the United States and foreign countries and
changes in the structure of the healthcare system or healthcare
payment systems; risks related to our ability to obtain new
corporate collaborations or licenses and acquire new technologies
or businesses on satisfactory terms, if at all; risks related to
our ability to successfully integrate and derive benefits from any
technologies or businesses that we license or acquire, including
but not limited to our acquisition of Assurex, Sividon and the
Clinic; risks related to our projections about the potential market
opportunity for our products; the risk that we or our licensors may
be unable to protect or that third parties will infringe the
proprietary technologies underlying our tests; the risk of
patent-infringement claims or challenges to the validity of our
patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading “Risk Factors” contained in
Item 1A of our most recent Annual Report on Form 10-K, which has
been filed with the Securities and Exchange Commission, as well as
any updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Media
Contact: |
Ron Rogers |
|
Investor
Contact: |
Scott Gleason |
|
(801) 584-3065 |
|
|
(801) 584-1143 |
|
rrogers@myriad.com |
|
|
sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024